Major Events - Meili Tianyuan Medical Health (02373) acquires 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan, aiming to capture the high-end beauty market in major cities [1] - Jinhai Medical Technology (02225) is actively preparing to participate in the 8th China International Import Expo [1] - China Biopharmaceutical (01177) has its selective MEK1/2 inhibitor TQ-B3234 included in the breakthrough therapy designation program [1] - Beijing Jiakesi plans to sell 90% of Jiakexi Health through capital increase and equity transfer agreements [1] - Green Power Environmental (01330) intends to invest in establishing a joint venture in Hong Kong to expand overseas environmental business [1] - Zhonghui Biotechnology (02627) applies for full circulation of H-shares [1] Operating Performance - Legend Holdings (03396) reports that its subsidiary, Legend New Science (003022.SZ), achieved a net profit attributable to shareholders of 232 million yuan in the first three quarters, an increase of 30.32% [1] - Mongol Mining (00975) reports total raw coal production of 3.6043 million tons from UHG and BN mines in the third quarter [1] - China Resources Power (00836) reports cumulative electricity sales of 161 million megawatt-hours from its subsidiary power plants in the first nine months, a year-on-year increase of 4.2% [1] - China Coal Energy (01898) reports coal sales of 19.66 million tons in September, a year-on-year decrease of 20.1% [1] - Air China (00753) reports a 1.2% year-on-year increase in passenger capacity input and a 5.6% year-on-year increase in passenger turnover in September [1]

Company News - China Coal Energy (01898.HK) reported a coal sales volume of approximately 190 million tons for the first nine months, a year-on-year decrease of 7.4%. In September, coal sales volume was 19.66 million tons, down 20.1% year-on-year [1] - China Southern Airlines (01055.HK) saw a 4.43% year-on-year increase in passenger capacity in September, with passenger turnover rising by 5.25%. The passenger load factor was 86.30%, an increase of 0.67 percentage points year-on-year. Cargo and mail turnover increased by 1.91% year-on-year [1] - China Eastern Airlines (00670.HK) reported a 3.63% year-on-year increase in passenger capacity for September, with passenger turnover up 8.67%. The passenger load factor was 87.57%, an increase of 4.06 percentage points year-on-year. Cargo and mail turnover rose by 10.95% year-on-year [1] - China Resources Power (00836.HK) achieved a cumulative electricity sales volume of 161 million MWh for the first nine months, an increase of 4.2% year-on-year, with wind power sales up 10.3% and solar power sales up 35.1% year-on-year [1] - Hopson Development Holdings (00754.HK) reported a total contract sales amount of 11.264 billion yuan for the first nine months, a year-on-year decrease of 12.62% [1] - China Design Group (01599.HK) won important project bids totaling approximately 3.175 billion yuan in the third quarter [1] - Jiumaojiu International Holdings (09922.HK) reported table turnover rates for its brands in the third quarter: 3.3 for Taier (self-operated only), 2.4 for Song Hotpot, and 2.5 for Jiumaojiu (self-operated only). Same-store average daily sales decreased by 9.3%, 19.1%, and 14.8% year-on-year, respectively, with the decline continuing to narrow [1][1] Financing and Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 2 million shares for a total of approximately 98.9589 million HKD, with a repurchase price range of 49.42 to 49.54 HKD [5] - Yum China (09987.HK) repurchased 18,800 shares for approximately 6.2596 million HKD, with a repurchase price range of 330.6 to 340.2 HKD [6] - HSBC Holdings (00005.HK) repurchased 4.721 billion HKD worth of shares, totaling 4.6216 million shares, with a repurchase price range of 101.1 to 103.2 HKD [7] - Qiniu Intelligent (02567) has cornerstone investor He Shun voluntarily extend the lock-up commitment, representing approximately 3.20% of the total issued shares [8] - China Galaxy (06881.HK) completed the issuance of 4 billion HKD short-term financing bonds with a final coupon rate of 1.66%, primarily for working capital replenishment [8] - Huaneng International Power (00902.HK) issued 3 billion HKD ultra-short-term financing bonds with an issuance rate of 1.50% [9]

连续调整后，AH医药资产今日（10月15日）终于迎来反弹，创新药大口回血，CXO等相关产业链同步 上行。 A股方面，CXO反弹集体，九洲药业大涨6%，康龙化成、昭衍新药涨超4%，规模最大医疗ETF （512170）场内收涨1.34%收复上日失地，全天成交5.89亿元。 近日医疗ETF（512170）围绕60日均线震荡，巨量资金开始"抄底"，近3日累计净买入超6.75亿元。今日 512170尚未收复60日线，或仍处于买盘区域。 A股创新药集体走强，华海药业领涨7.59%，兴齐眼药、三生国健、海思科齐涨逾5%，全市场唯一药 ETF（562050）重仓创新药，场内涨1.88%终结四连跌。 港股创新药涨势更甚，100%创新药研发标的——港股通创新药ETF（520880）午后稳步上行，场内收 涨2.12%，全天成交3.75亿元。 37只成份股35股收涨，绿叶制药领涨8.31%，亚盛医药-B、乐普生物-B、科伦博泰生物-B集体反弹逾 5%，百济神州、中国生物制药等核心权重股均收红。 资金动力来自何处？综合消息面和机构研判来看，创新药后续催化密集，或于四季度迎来第二波行情。 催化剂方面，2025年欧洲肿瘤内科学会（ESMO ...

TQ-B3234用于治疗成人PN的Ⅲ期註册临床研究已获CDE批准。该研究旨在更大规模的患者群体中确证 其疗效与安全性，以填补国内治疗空白。此次TQ-B3234纳入BTD，将加速药物上市进程，有望早日惠 及更多患者。 TQ-B3234是一款选择性MEK1/2抑制剂。MEK是细胞外信号相关激酶(ERK)通路的上游调节因子，MEK 抑制剂能够通过抑制RAS调节的RAF/MEK/ERK通路活性抑制肿瘤生长。 中国生物制药(01177)公布，该集团主导开发的国家1类新药TQ-B3234胶囊"选择性MEK1/2抑制剂"已被 中国国家药品监督管理局药品审评中心(CDE)纳入突破性治疗药物程序(BTD)，用于伴有症状、不能手 术的神经纤维瘤病I型(NF1)相关的成人丛状神经纤维瘤的治疗。 ...

Core Viewpoint - China National Pharmaceutical Group's TQ-B3234, a selective MEK1/2 inhibitor, has been included in the Breakthrough Therapy Designation (BTD) program by the Center for Drug Evaluation (CDE) for the treatment of symptomatic, unresectable neurofibromatosis type I (NF1) related plexiform neurofibromas in adults [1] Group 1 - TQ-B3234 is a selective MEK1/2 inhibitor that targets the RAS-regulated RAF/MEK/ERK pathway to inhibit tumor growth [1] - The Phase III registration clinical study for TQ-B3234 in treating adult plexiform neurofibromas has been approved by CDE, aiming to confirm its efficacy and safety in a larger patient population [1] - Inclusion in the BTD program will accelerate the drug's market launch process, potentially benefiting more patients sooner [1]

（於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 1 NF1是由NF1基因突變引起的常染色體顯性遺傳疾病，約佔所有神經纖維瘤病的96%，在中國新生兒 中預估發病率為百萬分之五[2]，2023年9月被納入中國《第二批罕見病目錄》。其中，約30%-60%的 NF1患者會發展為PN，導致疼痛、毀容甚至惡變。目前，手術是主要治療手段，但面臨高難度和易 復發等挑戰。 根據2025年《叢狀神經纖維瘤全病程管理專家共識》，對於無法手術的患者，首選MEK抑制劑進行靶 向治療以控制疾病。MEK抑制劑已證實在兒童患者中有效並有藥物在中國獲批上市，但國內的成人 PN患者目前仍缺乏有效治療藥物，治療需求遠未得到滿足。 TQ-B3234用於治療成人PN的Ⅲ期註冊臨床研究已獲CDE批准。該研究旨在更大規模的患者群體中確 證其療效與安全性，以填補國內治療空白。此次TQ-B323 ...

Core Insights - The 2025 European Society for Medical Oncology (ESMO) annual meeting will take place in Germany from October 17 to 21, where several significant oral reports from domestic innovative pharmaceutical companies are expected to be disclosed [1] - China National Pharmaceutical Group is set to present key data on its CDK2/4/6 inhibitor, Kumosili, and HER2 dual-target ADC, TQB2102, highlighting its comprehensive coverage in the breast cancer treatment landscape [1] Industry Overview - Breast cancer is the second most common cancer globally, following lung cancer, and has the highest incidence and mortality rates among women [1] - The breast cancer market is highly competitive, particularly in the HR+/HER2- subtype, which accounts for approximately 65%-70% of all breast cancer cases [2] - The global market for CDK4/6 inhibitors is projected to approach $13 billion by 2024, with ongoing growth driven by products from Pfizer, Eli Lilly, and Novartis [2] Company Developments - Kumosili capsules, a new generation CDK2/4/6 inhibitor, are expected to receive approval for second-line treatment of HR+/HER2- locally advanced or metastatic breast cancer by the end of this year [3] - The company is also advancing its clinical trials for Kumosili in first-line and adjuvant settings, aiming for comprehensive coverage across treatment lines [3] - TQB2102, another product from China National Pharmaceutical Group, will present phase Ib clinical data for HER2-positive recurrent/metastatic breast cancer at ESMO [3] Competitive Landscape - The ADC market for HER2-positive breast cancer is evolving, with significant sales from existing products like DS-8201, which reached $3.8 billion last year and is projected to peak at $10 billion [4] - TQB2102 has been optimized in terms of target binding, toxin load, and payload compared to DS-8201, and has been recognized as a breakthrough therapy for multiple indications [4] - The company has a diverse pipeline covering various cancer types, including breast, colorectal, lung, bile duct, and gastric cancers, with several indications entering phase III clinical trials [4]

Core Viewpoint - The report from GF Securities initiates coverage on China Biopharmaceutical (01177) with a "Buy" rating, projecting EPS of 0.23, 0.26, and 0.28 CNY per share for 2025-2027, and a fair value of HKD 11.54 per share, highlighting the company's transformation from a generic drug manufacturer to an R&D-driven international pharmaceutical group [1][2]. Group 1 - The company has established a strong product matrix through self-research, mergers and acquisitions, and pipeline introductions, covering four core therapeutic areas: oncology, liver disease, respiratory system, and surgical/pain management [1][2]. - R&D investment has been increasing year-on-year from 2018 to the first half of 2025, with the R&D expense ratio rising from 9.9% to 18.1%, and R&D expenses reaching CNY 3.188 billion in the first half of 2025, with approximately 78% allocated to innovative drug development [2]. Group 2 - In the oncology field, key products include: - "Defu" combination therapy with Anlotinib, which is a flagship product, and its combination with anti-PD-(L)1 for first-line indications [2]. - HER2 dual antibody ADC TQB2102, which is leading globally and has entered Phase III for treating HER2 low-expressing and HER2-positive breast cancer [2]. - CDK2/4/6 inhibitor Kumosilib, a global first, has submitted for marketing approval for HR+/HER2- breast cancer [2]. - CCR8 monoclonal antibody LM-108, a global first, is currently in Phase II [2]. - In the respiratory field, PDE3/4 inhibitors are expected to become a blockbuster drug for COPD, with TQC3721 being in the second position globally [2]. - In the liver disease area, the pan-PPAR agonist Lanifibranor may become the first MASH drug in China, while FGF21 fusion protein could be the most effective MASH drug [2]. - In the surgical and pain management sector, the company has established four transdermal patch technology platforms, solidifying its position as a leader in transdermal formulations [2].

Core Viewpoint - GF Securities initiates coverage on China Biologic Products (01177) with a "Buy" rating, projecting EPS of 0.23, 0.26, and 0.28 CNY per share for 2025-2027, with a fair value of HKD 11.54 per share, highlighting the company's transformation from a generic drug manufacturer to an R&D-driven international pharmaceutical group [1][2] Group 1 - The company has established a strong product pipeline covering four core therapeutic areas: oncology, liver disease, respiratory system, and surgical/pain management, successfully transitioning from a generic drug company to an innovative pharmaceutical leader [1][2] - R&D investment has been increasing annually from 2018 to H1 2025, with the R&D expense ratio rising from 9.9% to 18.1%, and R&D expenses reaching CNY 3.188 billion in H1 2025, with approximately 78% allocated to innovative drug development [2] Group 2 - In the oncology field, key products include: - "DeFu" combination therapy with Anlotinib, which is a flagship product, expanding first-line indications through combination with anti-PD-(L)1 therapy, with approvals for SCLC, endometrial cancer, and renal cell carcinoma [2] - HER2 bispecific antibody ADC TQB2102, which is leading globally and is in Phase III for treating HER2 low-expressing and HER2-positive breast cancer [2] - CDK2/4/6 inhibitor Kumosi Li, the world's first of its kind, has submitted for marketing approval for HR+/HER2- breast cancer [2] - CCR8 monoclonal antibody LM-108, a global first, is currently in Phase II [2] Group 3 - In the respiratory field, PDE3/4 inhibitors are expected to become a blockbuster drug for COPD, with TQC3721 being in the second position globally [2] - In the liver disease area, the pan-PPAR agonist Lanifibranor may become the first MASH drug in China, while FGF21 fusion protein could be the most effective MASH drug [2] - In the surgical and pain management sector, the company has established four transdermal patch technology platforms, solidifying its position as a leader in transdermal formulations [2]

机构：招银国际 研究员：武煜/黄本晨 维持买入评级。维持基于DCF 的目标价9.40 港元（WACC: 10.01%, 永续增长率：2.0%）。我们预计中 国生物制药2025E/ 26E/ 27E 收入增速为+19.1%/+4.4%/ +10.6% ，经调整净利润增速为+81.3%/ -30.0%/ +11.3%。出于谨慎考虑，我们暂未考虑潜在对外授权对收入和利润的贡献。 临床数据表明TQC3721 具备同类最佳潜力。 TQC3721 6mg 组在4 周治疗后的FEV1峰值比安慰剂组高 147ml，与恩司芬群12周临床数据（146/ 147ml。 非头对头数据比较，下同）一致，FEV1 AUC（0-12h）比安慰剂高87ml，也与恩司芬群12 周数据 （87/94ml）处在同一水平。值得注意的是，TQC3721 临床试验的全部受试者均已接受COPD 药物治 疗，其中30%的受试者使用了LAMA（长效抗胆碱能药物），70%同时使用LABA（长效β2 受体激动 剂）和LAMA 药物，而恩司芬群的临床实验中约38%的受试者为初治患者。因此，TQC3721 的临床入 组的患者基线更差。考虑到实际生活中COPD患者普遍 ...